Andy Chen
Stock Analyst at Wolfe Research
(2.73)
# 2,659
Out of 4,893 analysts
39
Total ratings
40.74%
Success rate
0.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRNA Verona Pharma | Initiates: Outperform | $170 | $104.85 | +62.14% | 1 | Jul 1, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Outperform | $49 | $46.27 | +5.90% | 1 | Jun 17, 2025 | |
| SRPT Sarepta Therapeutics | Initiates: Peer Perform | n/a | $19.07 | - | 1 | Jun 17, 2025 | |
| RNA Avidity Biosciences | Initiates: Outperform | $55 | $31.47 | +74.77% | 1 | Jun 17, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Peer Perform | n/a | $129.33 | - | 1 | Jun 3, 2025 | |
| MLTX MoonLake Immunotherapeutics | Upgrades: Outperform | $61 | $48.88 | +24.80% | 3 | May 19, 2025 | |
| NTLA Intellia Therapeutics | Upgrades: Outperform | $21 | $12.16 | +72.70% | 2 | Apr 21, 2025 | |
| ANAB AnaptysBio | Initiates: Outperform | n/a | $26.06 | - | 1 | Feb 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Initiates: Peer Perform | n/a | $31.97 | - | 1 | Feb 4, 2025 | |
| ETNB 89bio | Initiates: Outperform | n/a | $10.77 | - | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $14.08 | +42.05% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $49 | $24.35 | +101.23% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $19 | $12.07 | +57.42% | 1 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $17.50 | - | 2 | Jan 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $697 | $563.31 | +23.73% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $322.58 | - | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $70.34 | - | 1 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $22.68 | - | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $65 | $45.21 | +43.77% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $52.00 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $314.64 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $17.12 | - | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $8.67 | - | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $42.38 | - | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Peer Perform | n/a | $59.00 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $11.57 | +46.93% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $479.53 | - | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $96.66 | -56.55% | 1 | Feb 15, 2024 |
Verona Pharma
Jul 1, 2025
Initiates: Outperform
Price Target: $170
Current: $104.85
Upside: +62.14%
BridgeBio Pharma
Jun 17, 2025
Initiates: Outperform
Price Target: $49
Current: $46.27
Upside: +5.90%
Sarepta Therapeutics
Jun 17, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $19.07
Upside: -
Avidity Biosciences
Jun 17, 2025
Initiates: Outperform
Price Target: $55
Current: $31.47
Upside: +74.77%
Blueprint Medicines
Jun 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $129.33
Upside: -
MoonLake Immunotherapeutics
May 19, 2025
Upgrades: Outperform
Price Target: $61
Current: $48.88
Upside: +24.80%
Intellia Therapeutics
Apr 21, 2025
Upgrades: Outperform
Price Target: $21
Current: $12.16
Upside: +72.70%
AnaptysBio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $26.06
Upside: -
Crinetics Pharmaceuticals
Feb 4, 2025
Initiates: Peer Perform
Price Target: n/a
Current: $31.97
Upside: -
89bio
Feb 4, 2025
Initiates: Outperform
Price Target: n/a
Current: $10.77
Upside: -
Feb 4, 2025
Initiates: Outperform
Price Target: $20
Current: $14.08
Upside: +42.05%
Feb 4, 2025
Initiates: Outperform
Price Target: $49
Current: $24.35
Upside: +101.23%
Feb 4, 2025
Initiates: Outperform
Price Target: $19
Current: $12.07
Upside: +57.42%
Jan 3, 2025
Downgrades: Peer Perform
Price Target: n/a
Current: $17.50
Upside: -
Nov 12, 2024
Upgrades: Outperform
Price Target: $697
Current: $563.31
Upside: +23.73%
Nov 12, 2024
Downgrades: Underperform
Price Target: n/a
Current: $322.58
Upside: -
Oct 1, 2024
Initiates: Outperform
Price Target: n/a
Current: $70.34
Upside: -
Sep 27, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $22.68
Upside: -
Aug 26, 2024
Upgrades: Outperform
Price Target: $65
Current: $45.21
Upside: +43.77%
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $52.00
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $314.64
Upside: -
Jun 11, 2024
Initiates: Outperform
Price Target: n/a
Current: $17.12
Upside: -
May 14, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $8.67
Upside: -
Apr 10, 2024
Upgrades: Outperform
Price Target: n/a
Current: $42.38
Upside: -
Feb 15, 2024
Initiates: Peer Perform
Price Target: n/a
Current: $59.00
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $17
Current: $11.57
Upside: +46.93%
Feb 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $479.53
Upside: -
Feb 15, 2024
Initiates: Outperform
Price Target: $42
Current: $96.66
Upside: -56.55%